---
title: "Psychiatrist Details Lindsay Clancy’s Deteriorating Mental State Before Fatal Incident"
url: https://projectchintan.com/article/lindsay-clancy-trial-psychiatrist-testimony-medication-history-b74ir
publisher: Project Chintan
author: Project Chintan Newsroom
published: 2026-08-08T06:10:00.000Z
modified: 2026-08-08T11:24:29.770Z
language: en-IN
---

# Psychiatrist Details Lindsay Clancy’s Deteriorating Mental State Before Fatal Incident

Dr. Jennifer Tufts testified regarding the clinical timeline of Lindsay Clancy’s psychiatric treatment, revealing a pattern of escalating depression and medication adjustments. Court records indicate that despite multiple professional interventions, Clancy reported feeling numb and flat just hours b

## Key takeaways

- Dr. Jennifer Tufts testified that Lindsay Clancy denied homicidal or suicidal thoughts just one day before the killings occurred.
- Medical notes from early January 2023 indicate that Clancy’s mental health was deteriorating despite multiple medication changes.
- Clancy sought ketamine therapy for rapid relief of treatment-resistant depression but was told she did not yet meet the insurance requirements.
- The psychiatrist observed a 'flat affect' and forced bonding with her child, Callan, during January clinical visits.

## Background

The murder trial of Lindsay Clancy continued on August 7, 2026, with focused testimony from Dr. Jennifer Tufts, a psychiatrist who managed Clancy’s care during the final months of 2022 and early 2023. The prosecution’s line of questioning centered on the clinical assessments and medication changes implemented as Clancy struggled with postpartum mental health issues.

## Trial Testimony and Clinical Observations

Dr. Tufts detailed a series of appointments beginning in late 2022. During a session on December 16, 2022, Clancy disclosed a visit to Massachusetts General Hospital due to suicidal thoughts, though she declined an inpatient program at McLean Hospital. By December 21, Clancy reported a feeling that she was going to die, even while denying specific suicidal plans. During this period, Tufts considered a diagnosis of bipolar disorder but determined Clancy failed to meet the criteria, noting an absence of mania or grandiosity.

As January 2023 progressed, Tufts noted that Clancy’s condition was deteriorating. On January 6, Clancy described herself as feeling numb and attributed her persistent depression to the medication Seroquel. By January 11, Clancy inquired about ketamine therapy to achieve faster relief, though Tufts advised that insurance typically requires trying four different antidepressants first. On January 16, Clancy admitted that her attempts to bond with her infant son, Callan, felt forced.

## The Final Appointment

The most critical testimony involved a meeting on January 23, 2023—exactly one day before the killings. Tufts observed that Clancy appeared depressed with a flat affect. Despite reporting that she had to force herself to leave the house, Clancy again denied having any suicidal or homicidal thoughts. Tufts testified that Clancy’s speech and thought processes seemed appropriate and that her attire was suitable for the appointment. During this final visit, Tufts increased the dosage of Amitriptyline to 20 milligrams to address insomnia, unaware of the tragedy that would unfold within the next 24 hours.

## Key Facts

- Clancy was prescribed a rotating list of medications including Prozac, Ativan, Seroquel, Trazodone, and Amitriptyline.
- On January 6, 2023, Dr. Tufts officially noted that Clancy’s clinical condition was deteriorating.
- Clancy repeatedly denied homicidal or suicidal ideation during her final appointment on January 23.
- The defense is scheduled to begin cross-examination of Dr. Tufts on Monday.
- Medical records show Clancy sought specialized care at South Shore Hospital and Women & Infants Hospital in Rhode Island.

Source: The Boston Globe

---
Canonical: https://projectchintan.com/article/lindsay-clancy-trial-psychiatrist-testimony-medication-history-b74ir
Reported from: The Boston Globe